logo
搜索
菜单

safety的搜索结果

当前1/5页
排序: 最近更新
14.11: Imaging Studies for Cardiovascular System IV: CMRI 01:21 min
14.11: Imaging Studies for Cardiovascular System IV: CMRI
14.10: Imaging Studies for Cardiovascular System III: X-Ray 01:20 min
14.10: Imaging Studies for Cardiovascular System III: X-Ray
5.17: Behavior Modification 01:21 min
5.17: Behavior Modification
4.15: Narcolepsy 01:07 min
4.15: Narcolepsy
4.12: REM Sleep Behavior Disorder 01:15 min
4.12: REM Sleep Behavior Disorder
25.15: Dipeptidyl Peptidase 4 Inhibitors 01:23 min
25.15: Dipeptidyl Peptidase 4 Inhibitors
17.12: Dose Response Curve: Conventional Versus Nonmonotonic 01:21 min
17.12: Dose Response Curve: Conventional Versus Nonmonotonic
13.26: Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy 01:26 min
13.26: Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
12.17: Pharmacokinetics: Drug–Drug Interactions 01:25 min
12.17: Pharmacokinetics: Drug–Drug Interactions
12.2: Dosage Regimens: Partial Pharmacokinetic Parameters 01:01 min
12.2: Dosage Regimens: Partial Pharmacokinetic Parameters
11.7: FDA Approved Drugs: Changes to Approved Drugs 01:26 min
11.7: FDA Approved Drugs: Changes to Approved Drugs
11.3: Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence 01:19 min
11.3: Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
9.17: Drug Products: Biologics, Biosimilars and Interchangeables 01:28 min
9.17: Drug Products: Biologics, Biosimilars and Interchangeables
13.5: Design Example: Distributing Reinforcements in Concrete Sections 01:22 min
13.5: Design Example: Distributing Reinforcements in Concrete Sections
Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy 10.3791/3400-v 09:13 min
Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy
7.16: Three-Compartment Open Model 01:06 min
7.16: Three-Compartment Open Model
Production and Titering of Recombinant Adeno-associated Viral Vectors 10.3791/3348-v
Production and Titering of Recombinant Adeno-associated Viral Vectors
5.15: Factors Affecting Drug Biotransformation: Biological 01:19 min
5.15: Factors Affecting Drug Biotransformation: Biological
3.1: Drug Administration and Therapy Phases: Overview 01:26 min
3.1: Drug Administration and Therapy Phases: Overview
1.12: Drug Control Governance: Regulatory Bodies and Their Impact 01:03 min
1.12: Drug Control Governance: Regulatory Bodies and Their Impact
返回顶部